Home › Compare › PMXSF vs FCPT

PMXSF vs FCPT: Dividend Comparison 2026

PMXSF yields 7692.31% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PMXSF wins by $4177739098279589.00M in total portfolio value
10 years
PMXSF
PMXSF
● Live price
7692.31%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4177739098279589.00M
Annual income
$4,073,565,928,588,968,500,000.00
Full PMXSF calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — PMXSF vs FCPT

📍 PMXSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPMXSFFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PMXSF + FCPT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PMXSF pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PMXSF
Annual income on $10K today (after 15% tax)
$653,846.15/yr
After 10yr DRIP, annual income (after tax)
$3,462,531,039,300,623,000,000.00/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, PMXSF beats the other by $3,462,531,039,300,623,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PMXSF + FCPT for your $10,000?

PMXSF: 50%FCPT: 50%
100% FCPT50/50100% PMXSF
Portfolio after 10yr
$2088869549139794.50M
Annual income
$2,036,782,964,294,484,200,000.00/yr
Blended yield
97.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

PMXSF
No analyst data
Altman Z
-40.9
Piotroski
2/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PMXSF buys
0
FCPT buys
0
No recent congressional trades found for PMXSF or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPMXSFFCPT
Forward yield7692.31% ✓6.05%
Annual dividend / share$2.00 ✓$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$4177739098279589.00M ✓$49.1K
Annual income after 10y$4,073,565,928,588,968,500,000.00 ✓$5,775.28
Total dividends collected$4170772265337663.00M ✓$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PMXSF vs FCPT ($10,000, DRIP)

YearPMXSF PortfolioPMXSF Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$779,931$769,230.77$11,401$700.92+$768.5K → PMXSF
2$56,904,315$56,069,789.30$13,064$864.84+$56.89M → PMXSF
3$3,884,151,673$3,823,264,055.84$15,051$1,072.48+$3884.14M → PMXSF
4$248,050,254,929$243,894,212,638.74$17,442$1,337.22+$248050.24M → PMXSF
5$14,822,056,221,428$14,556,642,448,653.80$20,340$1,677.08+$14822056.20M → PMXSF
6$828,776,618,419,079$812,917,018,262,150.50$23,880$2,116.57+$828776618.40M → PMXSF
7$43,367,472,132,823,630$42,480,681,151,115,220.00$28,241$2,689.36+$43367472132.80M → PMXSF
8$2,123,871,047,251,591,000$2,077,467,852,069,469,400.00$33,660$3,442.07+$2123871047251.56M → PMXSF
9$97,358,102,514,598,310,000$95,085,560,494,039,100,000.00$40,456$4,439.95+$97358102514598.28M → PMXSF
10$4,177,739,098,279,589,000,000$4,073,565,928,588,968,500,000.00$49,063$5,775.28+$4177739098279589.00M → PMXSF

PMXSF vs FCPT: Complete Analysis 2026

PMXSF — Stock

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of oral pan-lysyl oxidase inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events, such as accidents, surgery,and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases, including kidney fibrosis, pulmonary fibrosis, liver fibrosis, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Full PMXSF Calculator →

FCPT — REIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this PMXSF vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PMXSF vs SCHDPMXSF vs JEPIPMXSF vs OPMXSF vs KOPMXSF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.